Zealand Pharma — December 2024
-
Zealand har første patient klar til nyt studie med sin kronjuvel https://proinvestor.com/investornyt/1252019/zealand-har-forste-patient-klar-til-nyt-studie-med-sin-kronjuvel
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1252711/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
DNB indleder dækning med Buy og kursmål 1050
-
DNB: We see petrelintide as potentially the first and
best-in-class amylin, offering GLP-1-like efficacy but with
better tolerability and weight-loss composition. We
expect a petrelintide profit-sharing agreement in H1
2025, with Roche as the most likely partner in our view.
We see its three obesity candidates having the potential
to reach a c8% share in a cUSD227bn market by 2042e. -
tak
-
Zealand Pharma får indledt dækning hos DNB med købsanbefaling https://proinvestor.com/investornyt/1252728/zealand-pharma-far-indledt-daekning-hos-dnb-med-kobsanbefaling
-
Bjæssing m.fl. - et fald på 76% er vel ret indlysende i forhold til en risikovurdering af selskaber som Gubra? Hvad sker der, når/hvis Gubra-amylin-studiet i et eller andet omfang ikke lever op til de ekstremt høje forventninger eller ligefrem fejler helt, og/eller man bliver overhalet indenom af andre aktører? God søndag
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1254082/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Vægttabsmidler får flere amerikanere til at søge læge https://proinvestor.com/investornyt/1254203/vaegttabsmidler-far-flere-amerikanere-til-at-soge-laege
-
WHO: Vægttabsmidler kan hjælpe med at stoppe fedmepandemien https://proinvestor.com/investornyt/1255431/who-vaegttabsmidler-kan-hjaelpe-med-at-stoppe-fedmepandemien
-
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome https://proinvestor.com/boards/123552
-
Av !
-
En langtrukken affære bliver trukket endnu længere ud. Syntes at huske at en af
konkurrenterne på området også er løbet ind i krav om yderligere dokumentationkrav. -
Måske - men, et afslag fra FDA er absolut ikke til at spøge med!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind